Ambu CEO predicts short-term shipping challenges for Core business

Shipment delays of Ambu's Core products won't distract CEO Juan José Gonzalez from focusing on creating sales growth within endoscopy.

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Published: 06.10.21 at 09:26

On Tuesday evening, Ambu downgraded its financial guidance for organic growth after global shipping delays have affected sales and increased costs of its Core business in the fourth quarter of the year.

However, the CEO at the medtech company Juan José Gonzalez emphasizes that the company regards these issues as short-term, and that the focus on its most important priority hasn't shifted – which is driving growth within the visualization segment, meaning the sales of endoscopes.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.